Clinical Trial Update: Safety of ToleroMune House Dust Mite (HDM) to Treat House Dust Mite Allergy in HDM Allergic Subjects With Rhinoconjunctivitis [Phase 2]

View source ↗

Summary

This clinical trial update notes the completion of a Phase 2 study evaluating the safety of ToleroMune for house dust mite allergy in subjects with rhinoconjunc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Allergic Rhinoconjunctivitis
• House Dust Mite Allergy

Drugs mentioned

• ToleroMune

Snippet

Sponsor: Circassia Limited | Conditions: Allergy | Phase 2 | Status: COMPLETED